[PDF][PDF] Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis
G Arrivi, M Verrico, M Roberto, G Barchiesi… - Cancer Management …, 2022 - Taylor & Francis
Background Retrospective studies and single center experiences suggest a role of
capecitabine combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs) …
capecitabine combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs) …
Management of gastric neuroendocrine tumors: a review
Gastric neuroendocrine tumors (G-NET) are rare tumors arising from enterochromaffin-like
cells of the gastric mucosa. They belong to a larger group called gastroenteropancreatic …
cells of the gastric mucosa. They belong to a larger group called gastroenteropancreatic …
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and …
JR Eads, TR Halfdanarson, T Asmis… - Endocrine-related …, 2023 - erc.bioscientifica.com
High-grade neuroendocrine neoplasms are a rare disease entity and account for
approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an …
approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an …
A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms
DH Owen, B Benner, L Wei, V Sukrithan, A Goyal… - Clinical Cancer …, 2023 - AACR
Purpose: Treatment options are limited in patients with metastatic neuroendocrine
neoplasms (NEN). We present the results for a phase II trial of combination nivolumab and …
neoplasms (NEN). We present the results for a phase II trial of combination nivolumab and …
Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review
DL Chan, EK Bergsland, JA Chan, R Gadgil… - The …, 2021 - academic.oup.com
Background Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs)
are often aggressive, and the optimal treatment is unclear for this subgroup of …
are often aggressive, and the optimal treatment is unclear for this subgroup of …
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Background The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP)
neuroendocrine neoplasms when Ki-67≤ 55% is unknown. A prospective multi-centre …
neuroendocrine neoplasms when Ki-67≤ 55% is unknown. A prospective multi-centre …
Pancreatic neuroendocrine neoplasms—update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) …
B Kos-Kudła, V Rosiek, M Borowska… - Endokrynologia …, 2022 - journals.viamedica.pl
In this paper, we present the current guidelines for the diagnostics and management of
pancreatic neuroendocrine neoplasms (PanNENs) developed by Polish experts providing …
pancreatic neuroendocrine neoplasms (PanNENs) developed by Polish experts providing …
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
L de Mestier, A Lamarca, J Hernando… - Endocrine-Related …, 2021 - erc.bioscientifica.com
There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We
aimed to describe the treatments received in patients with advanced G3 NETs and compare …
aimed to describe the treatments received in patients with advanced G3 NETs and compare …
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent …
M Passhak, MG McNamara, RA Hubner… - Best Practice & …, 2023 - Elsevier
Gastro-enterohepatic neuroendocrine tumours (GEP-NETs) represent a rare and highly
heterogeneous entity with increasing incidence. Based on the results obtained from several …
heterogeneous entity with increasing incidence. Based on the results obtained from several …
A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
MD Donadio, ÂB Brito… - … Advances in Medical …, 2023 - journals.sagepub.com
Background: Gastroenteropancreatic (GEP) neuroendocrine neoplasms with Ki-67> 20%
were subdivided in the most recent 2019 World Health Organization histopathological …
were subdivided in the most recent 2019 World Health Organization histopathological …